Since about 25 years a number of methods for recombinant synthesis of peptides and proteins were developed. These methods allow the production of large amounts of substances, which are used in clinical treatment (
e.g., growth factors, hormones, monoclonal antibodies and cytokines) (1). Because of their biochemical properties (high molecular weight, hydrophilia, sensitivity against chemicals, and proteolytic enzymes) these compounds cannot be administered orally, but require parenteral administration. Because these substances are often used for treatment of chronic diseases, this type of drug administration has negative effects on convenience and compliance of the patients. In order to solve this problem several methods for controlled injection or alternative administration of drugs were developed (1). Inhaled application (
via nose or mouth) of high molecular weight compounds seems to be a method of choice. However, several preconditions must be fulfilled to allow administration of adequate and reproducible drug doses for treatment of systemic diseases by inhaled aerosols. Firstly, these are biophysical and physiological factors (
e.g., aerosol particle size, and breathing maneuver (inspired volume, inspiratory flow, end-inspiratory breathhold time)), which are described in more detail in other reviews (2, 3). Others are the physical and biochemical stability of the pharmaceutical compounds designed for aerosolization (aqueous solution, dry powder, suspension or solution in propellants (4, 5)).
Since the lung has been exposed to microorganisms and foreign substances from
the environment for millions of years, during the evolution process a complex
defense system has been developed protecting the respiratory tract from the
nostrils down to the alveoli. The defense mechanisms of upper airways and the
bronchi consist of anatomic barriers, cough, mucociliary apparatus, airway epithelium,
secretory immunoglobulin A (IgA), dendritic cell network and lymphoid structure
(6). About 90% of inhaled particles with diameters larger than 2 to 3 µm are
deposited in the central airways on the mucus overlying the cilial epithelium
(2, 3, 6). After deposition they are rapidly transported to the trachea by means
of the mucociliary escalator and swallowed into the gastrointestinal tract (
Fig.
1). Furthermore, the thickness of mucus layer and respiratory epithelium
as well as peroxidases reduce the absorption of biomolecules deposited in the
central airways.
|
Fig. 1.
Uptake of inhaled drugs after peripheral/alveolar deposition (modified
according to (1)). |
Much better conditions for absorption of inhaled macromolecules are found in
the lung periphery making the lung an important target for inhalant administration
of pharmaceuticals for systemic treatment. Firstly, the size of the alveolar
surface depends on the distension of the lung and varies between 80 and 140
m
2, which is about the half of a tennis court
(132 m
2) and much larger than that of the nose
(about 180 cm
2) (4, 7, 8). Another advantage of
the lung is the thin alveolar epithelium. The thickness of this epithelium in
most regions is between 0.1 and 0.2 µm (9, 10) resulting in a total distance
between epithelial surface and blood between 0.5 and 1.0 µm (8), which is much
less than that in the bronchial tract, where the deposited substances have to
pass a distance of 30-40 µm, and more between mucus surface and blood (
Fig.
2) (8, 9). Furthermore, the lung is perfused with a blood volume of about
5 l/min at rest (11) without a first-pass effect, which plays a large role for
orally administered drugs even though some metabolism takes also place in the
lung (1, 4, 8, 10, 12, 13). However, even in the lung periphery a number of
defense mechanisms exist that inhibit the absorption of biomolecules,
e.g.,
macrophage uptake.
|
Fig.
2. Lung epithelium and mechanisms of particle deposition at different
sites within the lungs [modified from (9)]. Lung epithelial cells of the
different lung regions are drawn at their relative sizes. The higher the
number of the airway generation the deeper the particle is inspired into
the lung (0: Trachea, 1-2: Bronchi, 3-5: Bronchioles, 17-18: Terminal
bronchioles, 19-20: Respiratory bronchioles, 21-22: Alveolar ducts, 23:
Alveolar sacs). Mechanisms of particle deposition depending on the aerodynamic
particle diameters (dae) are impaction
(inertia), sedimentation (gravity) and diffusion (Brownian motion) in
bronchi, terminal bronchioles and alveoli, respectively. A typical aerosol
particle (dae: 2 µm) contains tens to
hundreds of millions of insulin molecules or hundreds of millions/billions
small molecules depending on its physical character (liquid or solid).
Solid aerosol particles are too large to be absorbed in total and must
dissolve to release their drugs for absorption. The deeper an aerosol
particle penetrates into the lung the thinner becomes the airway epithelium
and the larger becomes the lung surface. In consequence, the function
of the epithelial absorption barrier decreases and the absorption increases
as a function of the particle penetration depth into the lung. Typical
cells in the bronchi are basal cells, which serve as the stem or progenitor
cells for the other epithelial cells in case of injury or apoptosis, ciliated
cells, which provide the mechanism for moving the mucus blanket, goblet
cells, which secrete the mucus and brush cells, which are involved in
drug metabolism. The same cells and the mucus layer are also found in
the smaller airways, but not as tall. The thinnest absorption barrier
is found in lung alveoli. The basement membrane is not a membrane, but
an extracellular matrix of different biopolymers to which epithelial cells
attach. |
Physical methods for aerosol administration
Different types of nebulizers, metered dose inhalers (MDI), and powder inhalers have been developed for aerosol therapy. Requirements for this type of administration are high efficiency of drug delivery, reproducible dosing, targeted delivery of the inhaled drug to the site of action, ease of device operation, short duration of treatment, minimized risk to the patient and the medical personnel, environmental protection, and cost-effectiveness (14). However, the various products differ strongly in respect to their suitability for nebulization and administration of the different compounds. In the past, low rates of pulmonary drug absorption were observed, because the used nebulizers were not qualified for production of an adequate aerosol particle spectrum (5, 8) and did not take care on the breathing patterns of the patients.
Nebulizers
The appropriateness of nebulizers for administration of macromolecular compounds
depends on the performance of them (
e.g., aerosol output, distribution
width, and variability of the aerosol particle spectrum) as well as the stability
of the biochemical compounds used for nebulization. Within the nebulization
process in air-jet nebulizers, protein structure and function can be compromised
independently from the molecular weight of the protein (
Table 1) by surface
denaturation, shear-stress induced denaturation, and desiccation of the aerosol
droplets (4). The role of these degenerative processes in aerosol production
is enhanced by the operating mode of air-jet nebulizers, because just 1% of
the produced droplets leaves the nebulizer, whereas the other 99% remain inside
and undergoes the nebulization process at least 10-15 times (1, 4). Several
additives, such as lipids, surfactant, amino acids, albumin, polyols, and packing
into liposomes result in an increased protein stability and additional absorption
enhancement (4, 5, 15-17).
Table 1.
Stability of selected biomolecules in air-jet nebulizers (from (4)). Molecular
weight for some compounds not provided for monomers. |
|
Ultrasonic nebulizers act by disruption of liquid surfaces by means of ultrasound
and, therefore, allow production of high concentration aerosols (16). That requires
a supply of high energy doses, which especially in viscous liquids may cause
formation of large surfaces with cavitation and distinct heat development (4,
16). However, most of the clinically used pharmaceuticals have a sufficient
stability and are not affected by these denaturating processes. In contrast,
peptides and proteins (
e.g., insulin,
-interferon,
surfactant, and recombinant consensus interferon (rConIFN)) are irreversibly
denaturated (4, 16). Usually, aerosol particles produced with this type of nebulizers
are not appropriate for deep lung delivery.
Another approach for nebulization is the vibrating plate technology. In this type of aerosol devices, a liquid aerosol is produced by means of a vibrating mesh or plate with multiple apertures. Devices of this type allow the generation of aerosols with a high fine-particle fraction. The aerosols are generated as a fine mist without requirement of an internal baffling system (14, 16). Compared with conventional jet nebulizers and ultrasonic nebulisers, they have a higher efficiency for the delivery of drugs to the respiratory tract. Some other advantages are that these devices effectively aerosolize solutions, have only a minimal residual volume of medication left in the device (cost sparing effect), and might be breath-actuated, thereby limiting the release of aerosolized drugs into the environment (14). These devices sometimes fail when liposomal formulations should be aerosolized and it usually is difficult to aerosolize suspensions (exception: nanosuspensions).
Powder aerosols
Powder aerosols are produced by disaggregation of preformed (
e.g., milled
or spray-dried) micronized particles. The energy required for disaggregation
is supplied by the inhalation maneuver or alternatively by means of an external
energy (4, 18). Advantages of dry powder inhalers are their environmental sustainability
due to a propellant-free design, the ease to use, because not much patient coordination
is needed, and the formulation stability. On the other hand, typical disadvantages
are the dependency of the deposition efficiency on the patient’s inspiratory
airflow, their potential for dose uniformity problems, and their relative high
complexity and costs for development and manufacture. The use of dry powder
aerosols is established for treatment of asthma and chronic obstructive pulmonary
disease (COPD),
e.g., by means of ß-mimetics, anticholinergics,
or steroids. However, up to now there is little experience on inhalant administration
of biomolecules except insulin (Exubera
®) for
systemic treatment (1, 17, 18). This is caused by specific problems for the
use of proteins or peptides occurring in the processes of lyophilization or
spray drying, micronisation, completeness of dispersion and disaggregation,
and the surveillance of the latter.
For passive systems, the inspiratory air flow of the patient is an essential parameter. If this air flow is insufficient for complete disaggregation, large aggregates will be inhaled and cannot reach the alveolar region. Humidity can also be a large problem, because it impairs the stability of proteins and peptides, and also affects disaggregation and dispersion (4, 16, 18, 19). However, if the underlying problems, especially in particle engineering, are solved by novel techniques (20), the inhalation of dry powder aerosols may be an interesting tool for inhalant treatment of systemic diseases by inhaled biomolecules deposited in the alveolar region. In this case it should additionally be considered that high powder doses (over a few milligram) may cause cough and in that way influence deep lung deposition significantly.
Metered dose inhalers (MDI)
In metered dose inhalers compounds are dissolved or suspended in a pressurized propellant that should be nontoxic, noninflammable, compatible with drugs formulated, as suspensions or solutions, and to have appropriate boiling points and densities. For consistent dosing the vapor pressure must remain constant throughout the product´s life. These requirements are typically fulfilled by chlorofluorocarbons (
e.g., dichlorodifluoromethane, dichlorotetrafluoroethane, and trichlorofluoromethane), but not by pressurized carbon dioxide. After its release with high velocity, the mixture rapidly expands forming an aerosol. Because of the high velocity of the aerosol directly after its release, different types of spacers are often required for optimization of the aerosol deposition (4, 21). Aerosols from metered dose inhalers are established in clinical treatment of patients with asthma or COPD from about 50 years, and many different types of metered dose inhalers have been developed (4, 16, 21). Unfortunately, these devices, up to now, cannot be used for treatment with macromolecules (
e.g., peptides and proteins), because a number of prerequisites (stability of the compound within storage in the inhaler, no denaturation of the compound within the nebulization process, production of an aerosol with appropriate particle distribution pattern) are not sufficiently fulfilled.
ABSORPTION OF MACROMOLECULES DEPOSITED IN THE ALVEOLI
General and specific factors affecting the absorption
Proteins with lower molecular weight are absorbed more rapidly after alveolar
deposition than those with higher molecular weight (5, 8, 22-25). Numerous studies
have shown that the bioavailability of proteins with molecular weights up to
30 kDa (which includes the vast majority of proteins used in clinical therapy)
is between 20 and 50% (
Fig. 3) (8, 25). However, the bioavailability
of some proteins is much smaller, because they are subject of proteolytic degradation
(8, 22). Other variables affecting the absorption are pH-value, electrical charge,
surface activity, solubility and stability in the alveolar environment (4, 10,
22). Pharmacokinetics of the different macromolecules also depends on their
molecular weight. For example, the half-life time of the alveolar absorption
of hydrophilic compounds increases with their molecular weight (sucrose: MW:
342 Da, t
0.5: 87 min; inulin: MW: 5250 Da, t
0.5:
225 min; dextran: MW: 20000 Da, t
0.5: 688 min;
dextran: MW: 75000 Da, t
0.5: 1670 min) (22).
Accordingly, the time to reach the maximum serum concentration (
tmax.)
is also increasing as a function of the molecular weight of peptides and proteins
(
Fig. 4) (5, 22, 24, 25).
|
Fig.
3. Bioavailability of peptides and proteins after pulmonary deposition
or intratracheal adminstration (from (8, 25)). Data were obtained in rodents
( ), dogs
(), monkeys
() and
humans ().
Note the large variability of the bioavailability for some biomolecules
obtained in different experiments and species; the variability is in part
caused by a different mode of administration (i.e., intratracheal instillation
and aerosol inhalation). Data for albumin (MW: 68000 Da, bioavailability:
4.5%) and IgG (MW: 150000 Da, bioavailability: 1.7%) are not shown. Abbreviations:
CSA: Cyclosporine A; DDAVP: (desamino-Cys1-D-arg8)vasopressin; G-CSF:
Granulocyte-colony stimulating factor; GHRH: Growth hormone releasing
hormone; IFN-:
Interferon a; IFN-:
Interferon ;
PTH(1-84): Parathormone; PTH(1-34): Parathormone active fragment of 34
amino acids; RGD: Arg, Gly, Asp; VIP: Vasoactive intestinal peptide. |
|
Fig.
4. Time to reach the maximum blood concentration (tmax.)
after pulmonary administration as function of the molecular weight of
various peptides and proteins [modified from (5, 22, 24, 25)]. Most of
the biomolecules were administered intratracheally in rats, few in other
species (e.g. dogs). Data of some biomolecules show a large variability.
The variability can be caused by differences in the experimental settings
(e.g., animal species and mode of administration (substances administered
by aerosol peak more rapidly than those administered intratracheally))
and by the glycosylation of a protein. Abbreviations: AAT: 1-antitrypsin;
AATa): from E. coli, not glycosylated;
AATb): normal 1-antitrypsin,
glycosylated; CSA: Cyclosporine A; DDAVP: (desamino-Cys1-D-arg8)vasopressin;
G-CSF: Granulocyte-colony stimulating factor; GHRH: Growth hormone releasing
hormone; hGH: Human growth hormone; IFN-:
Interferon ;
LHRH: Luteinic hormone releasing hormone; PTH(1-34): Parathormone active
fragment of 34 amino acids; RGD: Arg, Gly, Asp. |
Proteins deposited on the mucociliar epithelium of the conducting airways are poorly absorbed and show a small bioavailability, because they are transported to the pharynx by mucociliary transport and degraded in the intestinal tract. In contrast, proteins deposited in the alveoli can be absorbed by four distinct mechanisms: phagocytosis by alveolar macrophages, paracellular diffusion
via tight junctions, vesicular endocytosis or pinocytosis, and receptor dependent transcytosis (4, 8, 10). The functional role of barriers and transport mechanisms is very different and underlies control by physiological and pharmacological factors (4, 8, 10, 15). For example, absorption enhancing substances (15) and cigarette smoking cause an inflammation of the lower respiratory tract followed by an increased epithelial permeability (8, 10). In consequence, inhaled insulin is more rapidly absorbed in smokers than in nonsmokers (5, 8, 10, 16, 17, 22, 26, 27). On the other hand, an alveolar inflammation, which can be even induced by the inhalation therapy itself (
e.g., by absorption enhancers), can result in a reduction of the bioavailability (15). However, an immunization against the administered peptides and proteins, which might cause an incompatibility or an inactivation, obviously plays no relevant role (8, 12, 28). Finally, pulmonary diseases affecting convective gas transport, size of the alveolar surface or alveolar permeability (asthma, COPD, smoking) can preclude or hamper a pulmonary drug therapy (8, 11, 17).
Physiological absorption barriers
A number of physiological barriers inhibit the absorption of inhaled proteins
after their pulmonary deposition (
Fig. 5) (4, 8, 10). The first barriers
after contact are the mucus layer and the alveolar lining fluid. The mucus layer
consists of a complex mixture of lipids and glycoproteins, but also surfactant
from the lower respiratory tract. The amount, composition and thickness of the
mucus layer depend on their localization in the respiratory tract and are also
influenced by local inflammatory and neuronal factors. Pulmonary diseases, local
inflammation, and administered drugs cause a variation of the mucus volume and
composition and of the airway diameters, all of which affects deposition and
absorption. In consequence, patients with pulmonary diseases must be thoroughly
investigated prior to inhalation therapy for treatment of systemic diseases,
because aerosol deposition and absorption differ from those in healthy individuals
and data obtained in individuals with normal lung function cannot be extrapolated
to these patients (4). The alveolar lining fluid includes a large amount of
surfactant with phospholipids and surfactant apolipoproteins acting as a surface
active substance. Hyperventilation causes a release of surfactant from the type
II pneumocytes located in the alveoli. However, numerous other endogenous and
exogenous factors (pharmaceuticals) modulate cellular surfactant synthesis.
Pulmonary surfactant interacts with the deposited substances affecting their
stability and solubility,
e.g., by formation of liposomes (
Fig. 5).
|
Fig. 5.
Barriers for absorption of peptides and proteins after peripheral/alveolar
deposition [modified from (4)]. |
Cells located in the respiratory tract also counteract the absorption of inhaled
substances after their alveolar deposition. Macrophages represent about 85%
of the cells retrieved by bronchoalveolar lavages and are normally the only
type of phagocytic cells within the lower respiratory tract (6). They play a
predominant role in this process for absorption inhibition, which serves as
an unspecific defense mechanism of the lung against bacteria and inhaled particles.
Lombry
et al (29) demonstrated that alveolar macrophages serve as a primary
barrier to the pulmonary absorption of macromolecules, as a depletion of alveolar
macrophages was followed by an improved absorption of proteins into circulation
after intratracheal instillation even though there seems to be differences regarding
the administered type of protein (
e.g., IgG and hCG). Macrophages are
differentiated from blood monocytes after they have emigrated into the tissues
and they occur in the respiratory tract, the alveoli, and the interstitial matrix,
and their number can rapidly increase in case of an inflammation (4, 6). Furthermore,
they can rapidly incorporate particles deposited in the lung alveoli, secrete
reactive oxygen species (ROS) by means of respiratory burst and release mediators
of inflammation (
e.g., granulocyte macrophage-colony stimulating factor
(GM-CSF)), cytokines (
e.g., IL-1ß/IL-1ra, IL-6 and tumor necrosis
factor a (TNF-
))
and chemokines (
e.g., RANTES and MCP-1-MCP-3) and enzymes (
e.g.,
metalloproteinase, urokinase and acid hydrolases) (
Fig. 5) (4, 6). The
release of inflammatory cytokines and chemokines causes an inflammatory cascade
with activation of neighbouring cells and invasion of other inflammatory cells
from the blood (6). Therefore, an increase in the number and activity of macrophages
in the alveolar lining fluid can substantially decrease the bioavailability
of inhaled biomolecules (4). Compared with macrophages, the proportion of neutrophil
granulocytes in alveoli is much smaller (about 1-2%), even though they are the
most abundant type of leukocytes in the body. Neutrophils can invade within
hours from circulation, where a large proportion is weakly bound by carbohydrate
ligands and selectins to the vascular endothelium, into the respiratory tract
and lung interstitium. The processes of granulocyte binding and extravasation
are triggered by several inflammatory cytokines and chemokines, which are in
part released from activated macrophages and mediated by an interaction between
adhesion molecules of leukocytes and endothelial cells (6). The physiological
role of neutrophil granulocytes is the elimination of microorganisms. For this
purpose they can phagocytose deposited material, secrete ROS and proteases (
e.g.,
cathepsin G and elastase) and release mediators of inflammation (TNF-
und IL-1) (4, 6). Hence, neutrophils can also account in a relevant manner for
the clearance of material deposited in lung alveoli. Another cell type, lymphocytes
are found in a proportion between 10 and 20% (50% CD4+ lymphocytes, 30% CD8+
lymphocytes, 10-15% natural killer cells, and 5% B lymphocytes) in bronchoalveolar
lavage fluid and also in pulmonary lymph nodes, and bronchial and alveolar interstitium.
Physiologically, they serve for the immunological response after antigen presentation
by macrophages and dendritic cells (6). Hence, deposition of immunogenic material
may cause a sensibilization of lymphocytes. However, lymphocytes can also phagocytose
and include secretory granules containing proteases and different proteolytic
enzymes (4).
The largest proportion of substances deposited in lung alveoli achieves the surface of the alveolar type I pneumocytes. These cells cover about 97% of the alveolar surface and serve for pulmonary gas exchange. The remaining area consists of the type II pneumocytes producing lung surfactant. Type I pneumocytes express carboxypeptidase on their membrane, which degrades a number of peptides and proteins. The total distance between respiratory tract and circulation is only 0.5 µm facilitating the diffusion of gasses and penetration and transport of fluids and (inhaled) macromolecules (4). Inhaled macromolecules can pass alveolar epithelium
via different transport mechanisms, which are intracellular tight junctions, membrane pores, and vesicular transport by type I and type II pneumocytes (4). Tight junctions are located between epithelial barriers, have a radius between about 0.8 and 1.0 nm and regulate the transport of small soluble substances, fluids, and ions. In the normal lung they play obviously no relevant role in the transport of proteins. In contrast, in cases of cellular damage the size selectivity is lost allowing permeation of larger molecules and fluid volumes. Furthermore, the permeability of chemical compounds like bile acids and calcium chelators is also increased. However, there are structural differences between epithelial tight junctions and endothelial tight junctions. The latter allow a permeation of molecules with molecular weights more than 12 kDa into the interstitium. In cases of hydrostatic or oncotic pressure gradients larger molecules can also permeate (4).
Membrane pores are discussed as another transport mechanism allowing the exchange
of fluids and macromolecules. It is assumed that pores of different sizes exist,
which can increase their diameter in case of an existing hydrostatic pressure
gradient (4). In pneumocytes types I and II another mechanism of vesicular transport
has been described, which is comparable with that in epithelial and endothelial
cells. This transport mechanism is of larger relevance in type I pneumocytes,
because they line a much larger proportion of the alveolar surface than type
II pneumocytes. In detail, the vesicular transport mechanism of type I pneumocytes
is pressure independent and allows the transcellular transport of fluids and
macromolecules. The vesicles have a diameter of about 35.5 nm allowing the transport
of even larger macromolecules. For example, the hydrodynamic radii of lysozyme
(MW: 14.1 kDa) and catalase (MW: 230 kDa) are 2.1 and 5.2 nm, respectively.
However, an estimation of the functional capacity of this transport mechanism
is difficult, because (1) the number of vesicles increases in liquid filled
lung indicating their role in the transport of fluids, (2) the glycocalix affects
the uptake of proteins
via specific or unspecific binding mechanisms
and a number of receptors and binding proteins were identified on capillary
endothelia, (3) the definite processing of the vesicles inside the cells and
the mechanisms for their movement (
e.g., Brownian movement) are not conclusively
identified, (4) the energetic mechanisms of membrane displacement and fusion
of the vesicles are not yet conclusively elucidated, and (5) different types
of vesicles (
e.g., clathrin-coated and clathrin-uncoated) exist, which
both play a role in transcytosis, but differ in respect to their characteristics
of protein uptake (
e.g.,
2-macroglobulin
and albumin). However, the results of investigations in type I pneumocytes indicate
that uptake and transport take place
via liquid phase, adsorption, and
receptor dependent processes (4).
In contrast to the type I pneumocytes described before, type II pneumocytes cover only a small area of the alveolar surface and produce pulmonary surfactant. The latter together with proteins plays an important role in the clearance of macromolecules by means of the alveolar lining fluid. Further cellular processing can take place with or without binding of the macromolecules on the cellular surface and depends strongly on the charge of the molecules. For example, cationic ferritin is absorbed much better than uncharged or anionic molecules. A large proportion of the material absorbed by endocytosis from the type II pneumocytes is deposited in lamellar bodies. In addition, transcellular transport represents another mechanism for absorption of macromolecules.
The basal lamina has a thickness of about 20 to 25 nm and is placed below the epithelium. It predominantly consists of glycoproteins (laminin, heparan sulphate, proteoglycan, fibronectin, and collagen) and has an anionic charge on its outer surface. Presumably, the latter regulates the permeation dependent on the size and charge of molecules. However, the mechanism of the permeation inhibition is not yet fully elucidated. After their passage through the alveolar wall and alveolar basal lamina inhaled substances reach the interstitium, where proteins can be bound by macromolecules or inactivated or phagocytosed by macrophages or transported to the lymphatic system. In the latter case, proteins can be detected after some hours in the circulation. The endothelial basal lamina and endothelium are also barriers for the absorption of macromolecules. However, compared with the other barriers described before they act only as a minor barrier for inhaled biomolecules before entering the circulation (4).
Methods for absorption improvement
A number of physiological barriers inhibit the absorption of macromolecules
via the gastrointestinal tract and other mucosal surfaces, the respiratory
tract, and the skin. In addition, various enzymes, especially peptidases and
proteases, degrade macromolecules, especially peptides and proteins, by proteolysis.
Addition of absorption enhancers to the pharmacological compound considerably
increases the transdermal (30), gastrointestinal (31), and respiratory absorption
(5, 15, 31, 32). Prevention of proteolysis by addition of protease inhibitors
or packing of the macromolecules into particles can further increase the bioavailability.
Packing into microparticles can also be used for the development of „sustained
release“ pharmaceuticals. However, it should be considered that all these substances
for absorption enhancement do not only affect the pharmacological properties
of the administered macromolecules (
e.g., bioavailability, time to reach
the maximum plasma concentration (tmax.), and maximum plasma concentration (C
max.)),
but also have an own active profile and toxicity (1, 15, 22).
Enzyme inhibitors
The activity of proteases and peptidases in the alveolar region of the respiratory
tract is much lower than in the gastrointestinal tract (13, 22). However, proteolytic
degradation, especially of susceptible peptides and proteins, cause a relevant
reduction of the bioavailability even after pulmonary administration of these
macromolecules. The bioavailability and pharmacological activity of inhaled
peptides and proteins can be improved by addition of protease inhibitors preventing
the inactivation of these biomolecules by proteolytic cleavage (1, 5, 15). Examples
of protease inhibitors are nafamostat mesilate (doubling the insulin bioavailability)
and aprotinin and (p-amidinophenyl)- methanesulfonylfluoride•HCl (p-AMF) (increase
the bioavailability of rhG-CSF 1.5-times and 3-times, respectively) (
Table
2) (15).
Table 2.
Substances tested for promoting pulmonary protein absorption of pharmaceuticals
for systemic treatment (modified from (15, 34-36)). Most substances were
tested in animals only and the absorption enhancing effect differs strongly
between the various compounds and the administered doses. Note that liposomes
and microparticles differ strongly regarding their composition. |
|
Surface active substances
This group includes compounds, which are very different in their molecular structure
(bile acids, fatty acids, nonionic detergents). The mode of action is not yet
completely understood, and it is assumed that the increase of the alveolo-capillary
transport is caused by an interaction with the cell membrane resulting in a
liquefaction followed by an increased permeability and/or a modulation of cellular
tight junctions followed by an increased paracellular permeability (15, 33).
Presumably, bile acids increase the absorption by alteration of the mucus layer,
protection of proteins against enzymatic degradation, disaggregation of protein
multimers, opening of epithelial tight junctions, and solubilization of phospholipids
and proteins out of the cell membrane, followed by formation of micelles. However,
the strong absorption enhancing effect (
e.g., of bile acids for insulin)
(5) can result in a damage to the epithelial surfaces after treatment for longer
periods. The absorption can also be increased by fatty acids (or their sodium
salts) or nonionic detergents. For example, beside other fatty acids (or their
sodium salts), oleic acid and linoleic acid and polyoxyethylene cause a distinct
increase of calcitonin absorption. Lauryl ether enhances the absorption of rhG-CSF
and Span 85 increases the absorption of inhaled insulin aerosol without lung
damage (
Table 2) (5, 15).
Cyclodextrins
Cyclodextrins are cyclic polymers of glucose that form complexes with molecules
fitting into their lipophilic inner structure. An absorption enhancing effect
of cyclodextrins was observed for luteinic hormone releasing hormone (LH-RH),
granulocyte-colony stimulating factor (G-CSF), calcitonin, and analogs of the
adrenocorticotrophic hormone (ACTH). However, inhalation of insulin with different
compounds of this group demonstrated that the intensity of the absorption enhancing
effect of cyclodextrins, but also their toxicity, depends on their structure
(1, 15). In detail, the toxicity increases with the intensity of absorption
enhancement (15). The underlying modes of action are solubilization and complexation
of membrane lipids and proteins of epithelial cells, inhibition of proteolytic
enzymes, and modification of the physicochemical properties (
e.g., solubility
and partition coefficient) of the administered substances. The latter is important
for hydrophilic peptides and proteins with high molecular weight that can only
partially be incorporated into complexes and are subject of changes of their
conformity (15) (
Table 2).
Other substances
Other very different compounds also serve as absorption enhancers for pharmaceuticals
after inhalant administration and pulmonary deposition. For example, salts of
different lanthanides (CeCl
3, GdCl
3,
LaCl
3, LuCl
3)
interact with membrane components and cause a conformational change of membrane
proteins resulting in a distinct increase of insulin absorption depending in
its intensity on the type of the lanthanide salt (15). Ethylene diamine tetraacetic
acid (EDTA) and salicylates increase the paracellular transport by a calcium
regulated modification of cellular tight junctions (15). Polyethylene glycol
(PEG) also increases the bioavailability of inhaled macromolecules (
e.g.,
rhG-CSF) after alveolar deposition (15). As shown for insulin, hydroxyl methyl
amino propionic acid (HMAP, an amino acid) increases absorption and bioavailability
of the inhaled peptide. However, the inhalation of HMAP is followed by a temporary
alveolar inflammation (15). In another study, the bioavailability of leuprolide
acetate was enhanced by additionally administered alcohol. However, repeated
administration resulted in an inflammation followed by a reduced effect (
Table
2) (15).
Another, recently described approach is the modification of therapeutic proteins
by fusion to the Fc domain of an IgG
1 (IgG subtype
1). The Fc fusion proteins can be efficiently administered as liquid aerosols
(38). Compared to the other absorption enhancers described before, the function
mode of this absorption enhancing process is more physiological. First described
in the intestine of rodents, the neonatal constant region fragment (Fc) receptor
(FcRn) transports maternal immunoglobulin (IgG) from milk into the circulation
of newborns providing immunity in the first life span. The transport is based
on the interactions between the Fc fragment of IgG and FcRn. In rodents FcRn
expression in gut epithelium rapidly decreases after weaning and remains low
in epithelial tissues of adult animals. In contrast, FcRn in humans is also
expressed in adulthood, where it can be found in the placenta and serves for
the transport of IgG from the mother to the fetus, and in several absorptive
tissues (lung, kidney, and intestine) (38, 39). Physiologically, IgG is taken
up into epithelial cells by pinocytosis. In detail, a coated vesicle is formed
by invagination of the plasma membrane entrapping IgG and other solutes in its
lumen. Obviously, only a small proportion of IgG binds to FcRn at the plasma
membrane, whereas most of the binding takes place intracellularly, because the
majority of FcRn is localized in acidic endosomal vesicles inside the cell.
The transport vesicles containing IgG bound to FcRn do not fuse with lysosomes,
but rather pass unidirectionally through the epithelial cell, driven by the
pH gradient between luminal and serosal exposures of the epithelial cells. As
the binding of IgG to FcRn is pH-dependent (tight binding at slightly acidic
pH), there is release of IgG from FcRn after fusion of the transport vesicles
with the plasma membrane at the basolateral site of the epithelial cells, because
of the neutral to slightly alkaline pH value of the interstitial space. Passage
of IgG into the circulation is most likely primarily paracellular because of
the absence of tight junctions between endothelial cells. The FcRn receptor
is also responsible for the long half-life time of IgG in the bloodstream, because
it protects IgG from degradation. As in epithelial cells, IgG is taken up from
vascular endothelial cells by pinocytosis. However, in contrast to epithelial
cells, IgG there is not subject of transcytosis, because the endocytic vesicles
containing IgG bound to FcRn return to the plasma membrane of the endothelial
cells, so that IgG is released back into the bloodstream. This results in a
recycling process for IgG protecting IgG from lysosomal degradation (39). Both,
the enhanced uptake
via alveolar epithelium and the endothelial recycling
process, makes the administration of Fc fusion proteins an interesting tool
for inhalant application of some proteins. Fc fusion proteins with erythropoietin,
interferon-a, interferon-b, and follicle-stimulating hormone (FSH) have been
evaluated in animals or humans, demonstrating a good tolerability, a high bioavailability
even of this large proteins, and an increased half-life time in the circulation
(
Table 2) (38-40, 44).
Liposomes and phospholipids
Liposomes are particles ranging in size from nanometers up to few micrometers
and consist of hydrophobic lipids and phospholipids forming a closed, concentric,
bilayer membrane vesicle with a hydrophilic aqueous centre (14). In their structure
they have some similarities to the biological cell membrane (
Fig. 6).
Each phospholipid molecule is characterised by a polar (
i.e., hydrophilic)
“head” group and two hydrophobic “tails”. Hydration of phospholipid molecules
under low-shear stress conditions results in a spontaneous arrangement of the
phospholipids in heads-up and tails-down orientation followed by a join in a
tail-to-tail array with formation of a concentric bilayer membrane enclosing
some water in an aqueous center (
Fig. 6). According to this structure
both hydrophobic and hydrophilic compounds can be packed into liposomes prior
to transportation into the lung. Hydrophilic compounds (
e.g., pharmaceuticals
and larger biomolecules) are entrapped into the vesicle inside the liposome,
whereas lipophilic (hydrophobic) compounds are encapsulated into the membrane
bilayer. Small liposomes are unilamellar bodies with a hydrophilic core, whereas
larger multilamellar liposomes have an onion-like structure with several layers
of phospholipids and aqueous compartments. Because of their strong chemical
and structural similarity liposomes merge with cell membranes and facilitate
drug delivery into the interior of the cell (
Fig. 6). In the lung, the
cellular absorption can also be influenced by the pulmonary surfactant that
lines the alveolar surface, because surfactant proteins A, B, and C are subject
to an intensive recycling process, which is further increased by the deposited
liposomes resulting in an enhanced protein absorption (15). One more mechanism
for liposome absorption is cellular phagocytosis, which seems to play a role
for small liposomes only (14). Depending on their structure liposomes have a
high transport capacity and allow the transport of a large number of very different
lipophilic and hydrophobic compounds. One more characteristic is the sustained
release of the compounds transported by liposomes (5, 14-16). The majority of
studies revealed no relevant toxicity of liposomes after pulmonary deposition.
However, liposomes not only enhance absorption of drugs and biomolecules, but
may also damage pulmonary epithelium. Both effects, absorption enhancement and
lung toxicity, depend on the physicochemical properties of liposomes (concentration,
charge, chain length, and molecular weight of phospholipids) (1, 14, 15). After
pulmonary deposition, soluble compounds are rapidly cleared from the lung, whereas
lipids and phospholipids remain much longer in the lung because of their chemical
properties and structural homology to cell membranes. Human studies demonstrated
that more than 80% and 52-73% of inhaled liposomal formulation remained in the
lung 8 and 24 hours after inhalation, respectively (14). Examples for the successful
administration of macromolecules for systemic treatment
via liposomes
are the inhalation of interleukin-2 (IL-2) in patients with advanced kidney
cancer, the inhalation of the immunosuppressive drug cyclosporine A in lung
graft recipients and even the inhalant administration of insulin (
Table 2)
(1, 4, 15, 16, 17, 45).
|
Fig.
6. Acceptance of a liposome into a cell. Liposomes consist of lipids
and phospholipids (from (14)). Each phospholipid has a polar hydrophilic
“head group” and two hydrophobic “tails”. When phospholipid molecules
are hydrated under low-shear conditions, they spontaneously arrange themselves
in sheets with their heads up and tails down. These sheets then join tails-to-tails
and form a bilayer membrane that encloses water and – if added – water
soluble compounds (e.g., pharmaceuticals and larger biomolecules) in the
center of the sphere. If liposomes come into contact with phospholipid
cell membranes, the liposome membrane fuses with the cell membrane facilitating
the entry of the encapsulated drug into the interior of the cell. |
Microparticles
In 1992, Rudt and Muller published their observation that smaller particles
are more rapidly phagocytosed than larger ones (46). Based on these results,
methods were developed to bind macromolecules to microparticles (1, 22, 43).
For this purpose proteins are packed into biologically degradable polymers or
lipids. That results in a reduction of physiological clearance in the alveolar
region and proteolytic degradation of peptides and proteins after phagocytosis
by alveolar macrophages. In addition, there is also a variation of the pharmacokinetics
of the administered pharmaceuticals, because of a sustained release of the compounds
from the microparticles (5, 22, 43). Microparticles for drug administration
can be classified into porous particles and liposomes (1, 5, 15, 22, 43). The
pharmacological properties of porous particles depend on the used material,
particle size, porosity, and surface structure, whereas those of liposomes depend
on particle size and chemical properties (charge, molecular weight) of the consisting
phospholipids (1, 15, 43). For example, inhaled insulin linked to large porous
particles shows a higher bioavailability than insulin from small nonporous particles
(47). The same applies to insulin administered
via liposomes and rhG-CSF
linked to polyethylene glycol (PEGylated CSF) (1, 17). However, it cannot be
excluded that microparticles can damage pulmonary tissue under specific conditions
(
Table 2) (1).
Examples of systemic treatment with inhaled macromolecules
Recently, the number of studies investigating the feasibility of macromolecules
for systemic treatment has continuously increased (
Table 3). Studies
in this field focussed on hormones (insulin, calcitonin, growth hormones, somatostatin,
thyroid-stimulating hormone (TSH), and follicle-stimulating hormone (FSH)),
growth factors (granulocyte-colony stimulating factor (G-CSF) and granulocyte
monocyte-colony stimulating factor (GM-CSF)), different interleukins and heparin
(unfractionated and low molecular weight heparin (LMWH)) (1, 4, 16, 17). Most
data are available for insulin, which was introduced in the market for pulmonary
delivery, heparin and interleukin-2 (IL-2) (4, 5, 8, 16, 22, 27, 35, 48-50).
Table 3.
Examples of aerosol inhalation for systemic treatment (from (4, 16, 22,
49, 51)). Note that the inhalant application of most substances is experimental
in animals or clinical studies or off-label use and not approved for human
use. Some cytokines tested in clinical studies failed to show a sufficient
antitumour effect even though there was a proven systemic effect of the
cytokine (51). Furthermore, for some substances an additional local mode
of action after inhalation has been described, which is not considered
in this table (4, 16, 51, 52). The table is not complete, but it demonstrates
the large variety of drugs, which have been administered by pulmonary
instillation or aerosol inhalation in clinical investigations or experimental
studies. |
|
#)Approximated
values; data in part for non-glycosylated monomers of peptides and proteins;
##) BAY 41-2272, BAY 41-8543, BAY 58-2667;
###) Phosphodiesterase inhibitors; ####)
Proteins with an arginine-glycine-aspartate sequence |
Safety of the inhalation of peptides and proteins
An analysis of safety and tolerability of pulmonary administered compounds includes their activity after inhalation, which can be largely different compared with subcutaneous administration. For example, inhaled insulin causes a more rapid decrease of the blood glucose concentration than subcutaneously administered insulin (8, 11, 12, 26-28). Pulmonary diseases may complicate or prevent inhalant drug therapy under some circumstances (8, 11, 17). Inhaled pharmaceuticals and additives may induce incompatibility. For example, peptides and proteins can cause immunisation (8, 10, 11, 28), but also can have specific effects on the target organ lung (
e.g., growth stimulating effect of insulin) (12, 28). In addition, a chronic administration of bile acids, cyclodextrins, and other absorption enhancers can damage alveolar epithelium (15, 28). Finally, administration of compounds by means of microparticles and liposomes can harm the lung (15). The latter, even though often a safe type of therapy, can damage the lung
via production of reactive oxygen species (ROS) in case of cationic liposomes (1).
A large number of studies have demonstrated the feasibility and safety of pulmonary administration of drugs and biomolecules for systemic treatment (8, 11, 16, 53). However, there are few data regarding the long-term effects of inhaled macromolecules, except insulin and heparin (1, 8, 11, 12, 16, 27, 28, 48, 50, 53, 82). The effects of inhaled macromolecules should be thoroughly investigated in future studies to ensure the safety of this pharmaceutical form for therapy. Packing of the macromolecules into microparticles and liposomes and addition of stabilisers or absorption enhancers can improve the bioavailability and reduce the required drug doses and therapy costs. Such compounds can strongly affect safety and tolerability of inhalant drug therapy. Therefore, they also should be subject of intensive studies, including lung function diagnostics for detection of therapy-induced untoward effects. In summary, advances in aerosol therapy in the last decades will allow the introduction of inhalation based methods for drug administration for treatment of systemic diseases as an alternative of subcutaneous injection and will improve convenience and compliance of the treated patients.
Conficts of interest:
Dr. RUdiger Siekmeier has no conflicts of interest in relation to this article.
Dr. Gerhard Scheuch does not have a financial relationship with a commercial
entity that has an interest in the subject of this manuscript. Dr. Scheuch is
a consultant for several pharmaceutical companies in the field of aerosol medicine
and pulmonary drug delivery (e.g., Bayer-Schering, Boehringer/Ingelheim, GSK,
Novartis, Talecris, Sandoz).
REFERENCES
- Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001; 2: 198-209.
- Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 2006; 58: 996-1008.
- Scheuch G, Siekmeier R. Novel approaches to enhance pulmonary delivery of proteins and peptides. J Physiol Pharmacol 2007; 58 (Suppl 5): 615-625.
- Niven RW. Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst 1995; 12: 151-231.
- Yu J, Chien YW. Pulmonary drug delivery: Physiologic and mechanistic aspects. Crit Rev Ther Drug Carrier Syst 1997; 14: 395-453.
- Nicod LP. Pulmonary defense mechanisms. Respiration 1999; 66: 2-11.
- Weibel ER. Morphometry of the Human Lung. Springer-Verlag, Berlin, 1963.
- Wolff RK. Safety of inhaled proteins for therapeutic use. J Aerosol Med 1998; 11: 197-219.
- Patton JS, Byron PR. Inhaling medicines: Delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007; 6: 67-74.
- Patton JS, Platz RM. Routes of delivery: Case studies. (2) Pulmonary delivery of peptides and proteins for systemic action. Adv Drug Deliv Rev 1992; 8: 179-196.
- Valente AXCN, Langner R, Stone HA, Edwards DA. Recent advances in the development of an inhaled insulin product. Biodrugs 2003; 17: 9-17.
- Cefalu WT. Concept, strategies, and feasibility of non-invasive insulin delivery. Diabetes Care 2004; 27: 239-246.
- Weibel ER. Morphometry of the human lung: The state of the art after two decades. Bull Eur Physiopathol Respir 1979; 15: 999-1013.
- Dhand R. New frontiers in aerosol delivery during mechanical ventilation. Respir Care 2004; 49: 666-677.
- Hussain A, Arnold JJ, Khan MA, Ahsan F. Absorption enhancers in pulmonary protein delivery. J Control Release 2004; 94: 15-24.
- Kohler D, Fleischer W. Medikamente. In Theorie und Praxis der Inhalationstherapie, D Köhler, W Fleischer (eds). Arcis Verlag, München, 2000, pp. 71-99.
- Siekmeier R, Scheuch G. Systemische Therapie mit Aerosolen. Beispiele zur pulmonalen Verabreichung von Makromolekülen zur systemischen Therapie. Atemw-Lungenkrkh 2005; 31: 391-410.
- Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care 2005; 50: 1209-1227.
- Irngartinger M, Camuglia V, Damm M, Goede J, Frijlink HW. Pulmonary delivery of therapeutic peptides via dry powder inhalation: Effects of micronisation and manufacturing. Eur J Pharm Biopharm 2004; 58: 7-14.
- Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev 2006; 58: 1009-1029.
- Newman SP. Principles of metered-dose inhaler design. Respir Care 2005; 50: 1177-1190.
- Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med 1994; 7: 49-75.
- Kobayashi S, Kondo S, Juni K. Critical factors on pulmonary absorption of peptides and proteins (diffusional barrier and metabolic barrier). Eur J Pharm Sci 1996; 4: 367-372.
- Patton JS, Trinchero P, Platz RM. Bioavailability of pulmonary delivered peptides and proteins: a-interferon, calcitonins and parathyroid hormones. J Control Release 1994; 28: 79-85.
- Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004; 1: 338-344.
- Barnett AH. Exubera inhaled insulin: A review. Int J Clin Pract 2004; 58: 394-401.
- Mastrandrea LD, Quattrin T. Clinical evaluation of inhaled insulin. Adv Drug Deliv Rev 2006; 58; 1061-1075.
- Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004; 43: 781-801.
- Lombry C, Edwards DA, Preat V, Vanbever R. Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. Am J Physiol Lung Cell Mol Physiol 2004; 286: L1002-L1008.
- Sinha VR, Kaur MP. Permeation enhancers for transdermal drug delivery. Drug Dev Ind Pharm 2000; 26: 1131-1140.
- Song Y, Wang Y, Thakur R, Meidan VM, Michniak B. Mucosal drug delivery: Membranes methodologies, and applications. Crit Rev Ther Drug Carrier Syst 2004; 21: 195-256.
- Davis SS, Illum L. Absorption enhancers for nasal drug delivery. Clin Pharmacokinet 2003; 42: 1107-1128.
- Edwards DA, Dunbar C. Bioengineering of therapeutic aerosols. Annu Rev Biomed Eng 2002; 4: 93-107.
- Kobayashi S, Kondo S, Juni K. Study on pulmonary delivery of salmon calcitonin in rats: Effects of protease inhibitors and absorption enhancers. Pharm Res 1994; 11: 1239-1243.
- Okamoto H, Todo H, Iida K, Danjo K. Dry powders for pulmonary delivery of peptides and proteins. Kona 2002; 20: 71-83.
- Sakagami M, Byron PR. Respirable microspheres for inhalation. The potential of manipulating pulmonary disposition for improved therapeutic efficacy. Clin Pharmacokinet 2005; 44: 263-277.
- Kobayashi S, Kondo S, Juni K. Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm Res 1996; 13: 80-83.
- Bitonti AJ, Dumont JA, Low SC et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci USA 2004; 101: 9763-9768.
- Bitonti AJ, Dumont JA. Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv Drug Deliv Rev 2006; 58: 1106-1118.
- Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med 2005; 18: 294-303.
- Grenha A, Remunan-Lopez C, Carvalho ELS, Seijo B. Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur J Pharm Biopharm 2008; 69: 83-93.
- Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 2001; 7: 3258-3262.
- Verschraegen CF, Gilbert BE, Loyer E et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 2004; 10: 2319-2326.
- Low SC, Nunes SL, Bitonti AJ, Dumont JA. Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum Reprod 2005; 20: 1805-1813.
- Huang YY, Wang CH. Pulmonary delivery of insulin by liposomal carriers. J Control Release 2006; 113: 9-14.
- Rudt S, Muller R. in vitro phagocytosis assay of nanoparticles and microparticles by chemiluminescence. 1. Effect of analytical parameters, particle size and particle concentration. J Control Release 1992; 22: 263-271.
- Edwards DA, Hanes J, Caponetti G et al. Large porous particles for pulmonary drug delivery. Science 1997; 276: 1868-1871.
- Guntur VP, Dhand R. Inhaled insulin: Extending the horizons of inhalation therapy. Respir Care 2007; 52, 911-922.
- Kohler D. Aerosols for systemic treatment. Lung 1990; 168 (Suppl.): 677-684.
- Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005; 50: 1161-1176.
- Thipphawong J. Inhaled cytokines and cytokine antagonists. Adv Drug Delivery Rev 2006; 58: 1089-1105.
- Wylam ME, Ten R, Prakash UBS, Nadrous HF, Clawson ML, Anderson PM. Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis. Eur Respir J 2006; 27: 585-593.
- Kohler D. Aerosolized heparin. J Aerosol Med 1994; 7: 307-314.
- Scheuch G, Brand P, Meyer T et al. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects. J Physiol Pharmacol 2007; 58 (Suppl 5): 603-614.
- Ryszka F, Dolinska B. Initial studies on the administration route of prolactin. Boll Chim Farm 2001; 140: 169-171.
- Anderson PM, Markovic SN, Sloan JA et al. Aerosol granulocyte macrophage-colony stimulating factor: A low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 1999; 5: 2316-2323.
- Okumu FW, Lee RY, Blanchard JD et al. Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. Pharm Res 2002; 19: 1009-1012.
- Davison S, Thippawong J, Blanchard J et al. Pharmacokinetics and acute safety of inhaled testosterone in postmenopausal women. J Clin Pharmacol 2005; 45: 177-184.
- Corcoran TE. Inhaled delivery of aerosolized cyclosporine. Adv Drug Deliv Rev 2006; 58: 1119-1127.
- Iacono AT, Johnson BA, Grgurich WF et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med 2006; 354: 141-150.
- Deshpande D, Blanchard J, Srinivasan S et al. Aerosolization of lipoplexes using AERx Pulmonary Delivery System. AAPS PharmSci 2002; 4: E13.
- Farr SJ, Otulana BA. Pulmonary delivery of opioids as pain therapeutics. Adv Drug Deliv Rev 2006; 58: 1076-1088.
- Evgenov OV, Kohane DS, Bloch KD et al. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med 2007: 176; 1138-1145.
- Heinzer H, Mir TS, Huland E, Huland H. Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J Clin Oncol 1999; 17: 3612-3620.
- Heinzer H, Huland E, Huland H. Regionale Immuntherapie beim metastasierten Nierenzellkarzinom. Urologie (A) 2002; 41: 239-248.
- Huland E, Heinzer H. Renal cell carcinoma - innovative medical treatments. Curr Opin Urol 2004; 14: 239-244.
- Skubitz KM, Anderson PM. Inhalational interleukin-2 liposomes for pulmonary metastases: A phase I clinical trial. Anticancer Drugs 2000; 11: 555-563.
- Shahiwala A, Misra A. A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: A technical note. AAPS PharmSciTech 2005; 6: E482-E486.
- http://www.solvaypharmaceuticals-us.com/newsroom/pressreleases/0,,28488-2-0,00.htm 2005.
- Schermuly RT, Krupnik E, Tenor H et al. Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. Am J Respir Crit Care Med 2001; 164: 1694-1700.
- Lauterbach R, Szymura-Oleksiak J, Pawlik D, Warchol J, Lisowska-Miszczyk I, Rytlewski K. Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: A pilot clinical study. J Matern Fetal Neonatal Med 2006; 19: 433-438.
- Aubin MC, Laurendeau S, Mommerot A et al. Differential effects of inhaled and intravenous sildenafil in the prevention of the pulmonary endothelial dysfunction due to cardiopulmonary bypass. J Cardiovasc Pharmacol 2008; 51: 11-17.
- Ichinose F, Erana-Garcia J, Hromi J et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 2001; 29: 1000-1005.
- Pullamsetti S, Krick S, Yilmaz H et al. Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. Respir Res 2005; 6: 128.
- Ichinose F, Adrie C, Hurford WE, Bloch KD, Zapol WM. Selective pulmonary vasodilation induced by aerosolized zaprinast. Anesthesiology 1998, 88: 410-416.
- Gupta S, Moussy F, Dalby RN, Miekka SI, Bruley DF. Pulmonary delivery of human protein C and factor IX. Adv Exp Med Biol 1997; 411: 429-435.
- Beyer S, Speich R, Fischler M, Maggiorini M, Ulrich S. Long-term experience with oral or inhaled vasodilator combination therapy in patients with pulmonary hypertension. Swiss Med Wkly 2006; 136: 114-118.
- Gessler T, Seeger W, Schmehl T. Inhaled prostanoids in the therapy of pulmonary hypertension. J Aerosol Med 2008; Jan 16 [Epub ahead of print].
- Onen ZP, Akkoca Yildiz O, Eris Gulbay B, Karabiyikoglu G. Inhaled iloprost
as a long-term additional therapy to oral sildenafil in severe idiopathic
pulmonary arterial hypertension. Tuberk Toraks 2006; 54: 177-181.
- Olschewski H, Rohde B, Behr J et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 2003; 124: 1294-1304.
- Schermuly RT, Inholte C, Ghofrani HA et al. Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: Amplification by different type phosphodiesterase inhibitors. Respir Res 2005; 6: 76.
- Ceglia L, Lau J, Pittas AG. Meta-analysis: Efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med 2006; 145: 665-675.